Skip to menu Skip to content Skip to footer

2017

Conference Publication

Mitochondrial dysfunction defines a population of young people with type 1 diabetes at risk of kidney disease

Forbes, J. M., Flemming, N. B., Mccarthy, D. A., Boot, K., De Silva, N., Gallo, L. A., Nisbett, J., Morton, A., Teasdale, S., Thorburn, D. R., Russell, A., Isbel, N., Johnson, D., Morahan, G., Jones, T., Couper, J., Donaghue, K., Hodson, M. P. and O'Moore-Sullivan, T. (2017). Mitochondrial dysfunction defines a population of young people with type 1 diabetes at risk of kidney disease. 53rd Annual Meeting of the European Association for the Study of Diabetes (EASD), Lisbon, Portugal, 11-15 September 2017. Richmond, VIC, Australia: Wiley-Blackwell Publishing Asia.

Mitochondrial dysfunction defines a population of young people with type 1 diabetes at risk of kidney disease

2017

Conference Publication

Mitochondrial dysfunction defines a population of young people with type 1 diabetes at risk of kidney disease

Forbes, J. M., Flemming, N., McCarthy, D., Boot, K., D'Silva, N., Gallo, L., Thorburn, D. R., Russell, A., Johnson, D., Morahan, G., Jones, T., Couper, J., Donaghue, K., Hodson, M. and O'Moore-Sullivan, T. (2017). Mitochondrial dysfunction defines a population of young people with type 1 diabetes at risk of kidney disease. 53rd Annual Meeting of the European-Association-for-the-Study-of-Diabetes (EASD), Lisbon Portugal, 11-15 September 2017. New York NY United States: Springer.

Mitochondrial dysfunction defines a population of young people with type 1 diabetes at risk of kidney disease

2016

Journal Article

Receptor for advanced glycation end products (RAGE) in type 1 diabetes pathogenesis

Leung, Sherman S., Forbes, Josephine M. and Borg, Danielle J. (2016). Receptor for advanced glycation end products (RAGE) in type 1 diabetes pathogenesis. Current Diabetes Reports, 16 (10) 100, 100. doi: 10.1007/s11892-016-0782-y

Receptor for advanced glycation end products (RAGE) in type 1 diabetes pathogenesis

2016

Journal Article

Dietary advanced glycation end-products aggravate non-alcoholic fatty liver disease

Leung, Christopher, Herath, Chandana B., Jia, Zhiyuan, Andrikopoulos, Sof, Brown, Bronwyn E., Davies, Michael J., Rivera, Leni R., Furness, John B., Forbes, Josephine M. and Angus, Peter W. (2016). Dietary advanced glycation end-products aggravate non-alcoholic fatty liver disease. World Journal of Gastroenterology, 22 (35), 8026-8040. doi: 10.3748/wjg.v22.i35.8026

Dietary advanced glycation end-products aggravate non-alcoholic fatty liver disease

2016

Conference Publication

Understanding Novel Genetic Factors Underlying Circulating Cystatin C and Kidney Function

Fotheringham, A., Balmer, L., Morahan, G. and Forbes, J. (2016). Understanding Novel Genetic Factors Underlying Circulating Cystatin C and Kidney Function. HOBOKEN: WILEY-BLACKWELL.

Understanding Novel Genetic Factors Underlying Circulating Cystatin C and Kidney Function

2016

Journal Article

Targeting advanced glycation with pharmaceutical agents: where are we now?

Borg, Danielle J. and Forbes, Josephine M. (2016). Targeting advanced glycation with pharmaceutical agents: where are we now?. Glycoconjugate Journal, 33 (4), 653-670. doi: 10.1007/s10719-016-9691-1

Targeting advanced glycation with pharmaceutical agents: where are we now?

2016

Journal Article

Diabetic kidney disease: a role for advanced glycation end-product receptor 1 (AGE-R1)?

Zhuang, Aowen and Forbes, Josephine M. (2016). Diabetic kidney disease: a role for advanced glycation end-product receptor 1 (AGE-R1)?. Glycoconjugate Journal, 33 (4), 645-652. doi: 10.1007/s10719-016-9693-z

Diabetic kidney disease: a role for advanced glycation end-product receptor 1 (AGE-R1)?

2016

Journal Article

Mitochondria-power players in kidney function?

Forbes, Josephine M. (2016). Mitochondria-power players in kidney function?. Trends in Endocrinology and Metabolism, 27 (7), 441-442. doi: 10.1016/j.tem.2016.05.002

Mitochondria-power players in kidney function?

2016

Conference Publication

Reduced Insulin Sensitivity Is Associated with Increased Glomerular Filtration Rate in Healthy Nondiabetic Individuals, Independent of Body Mass Index, Adiposity, and Blood Pressure

Naderpoor, Negar, Lyons, Jasmine G., Soldatos, Georgia, Mousa, Aya, Forbes, Josephine M. and De Courten, Barbora (2016). Reduced Insulin Sensitivity Is Associated with Increased Glomerular Filtration Rate in Healthy Nondiabetic Individuals, Independent of Body Mass Index, Adiposity, and Blood Pressure. 76th Scientific Sessions of the American-Diabetes-Association, New Orleans La, Jun 10-14, 2016. ALEXANDRIA: AMER DIABETES ASSOC.

Reduced Insulin Sensitivity Is Associated with Increased Glomerular Filtration Rate in Healthy Nondiabetic Individuals, Independent of Body Mass Index, Adiposity, and Blood Pressure

2016

Journal Article

Diet low in advanced glycation end products increases insulin sensitivity in healthy overweight individuals: a double-blind, randomized, crossover trial

de Courten, Barbora, de Courten, Maximilian P. J., Soldatos, Georgia, Dougherty, Sonia L., Straznicky, Nora, Schlaich, Markus, Sourris, Karly C., Chand, Vibhasha, Scheijen, Jean L. J. M., Kingwell, Bronwyn A., Cooper, Mark E., Schalkwijk, Casper G., Walker, Karen Z. and Forbes, Josephine M. (2016). Diet low in advanced glycation end products increases insulin sensitivity in healthy overweight individuals: a double-blind, randomized, crossover trial. American Journal of Clinical Nutrition, 103 (6), 1426-1433. doi: 10.3945/ajcn.115.125427

Diet low in advanced glycation end products increases insulin sensitivity in healthy overweight individuals: a double-blind, randomized, crossover trial

2016

Journal Article

Once daily administration of the SGLT2 inhibitor, empagliflozin, attenuates markers of renal fibrosis without improving albuminuria in diabetic db/db mice

Gallo, Linda A., Ward, Micheal S., Fotheringham, Amelia K., Zhuang, Aowen, Borg, Danielle J., Flemming, Nicole B., Harvie, Ben M., Kinneally, Toni L., Yeh, Shang-Ming, McCarthy, Domenica A., Koepsell, Hermann, Vallon, Volker, Pollock, Carol, Panchapakesan, Usha and Forbes, Josephine M. (2016). Once daily administration of the SGLT2 inhibitor, empagliflozin, attenuates markers of renal fibrosis without improving albuminuria in diabetic db/db mice. Scientific Reports, 6 (1) 26428, 28124. doi: 10.1038/srep26428

Once daily administration of the SGLT2 inhibitor, empagliflozin, attenuates markers of renal fibrosis without improving albuminuria in diabetic db/db mice

2016

Journal Article

Antigen-encoding bone marrow terminates islet-directed memory CD8+ T-cell responses to alleviate islet transplant rejection

Coleman, Miranda A., Jessup, Claire F., Bridge, Jennifer A., Overgaard, Nana H., Penko, Daniella, Walters, Stacey, Borg, Danielle J., Galea, Ryan, Forbes, Josephine M., Thomas, Ranjeny, Coates, Patrick T. C., Grey, Shane T., Wells, James W. and Steptoe, Raymond J. (2016). Antigen-encoding bone marrow terminates islet-directed memory CD8+ T-cell responses to alleviate islet transplant rejection. Diabetes, 65 (5), 1328-1340. doi: 10.2337/db15-1418

Antigen-encoding bone marrow terminates islet-directed memory CD8+ T-cell responses to alleviate islet transplant rejection

2016

Conference Publication

The SGLT2 Inhibitor, Empagliflozin, Attenuates Some Markers of Renal Fibrosis without Improving Albuminuria in Diabetic <i>Db</i>/<i>Db</i> Mice

Gallo, Linda A., Ward, Micheal S., Fotheringham, Amelia K., Zhuang, Aowen, Koepsell, Hermann, Vallon', Volker, Pollock, Carol, Panchapakesan, Usha and Forbes, Josephine M. (2016). The SGLT2 Inhibitor, Empagliflozin, Attenuates Some Markers of Renal Fibrosis without Improving Albuminuria in Diabetic Db/Db Mice. Experimental Biology Meeting, San Diego Ca, Apr 02-06, 2016. BETHESDA: FEDERATION AMER SOC EXP BIOL.

The SGLT2 Inhibitor, Empagliflozin, Attenuates Some Markers of Renal Fibrosis without Improving Albuminuria in Diabetic <i>Db</i>/<i>Db</i> Mice

2016

Journal Article

Deficiency in apoptosis-inducing factor recapitulates chronic kidney disease via aberrant mitochondrial homeostasis

Coughlan, Melinda T., Higgins, Gavin C., Tuong-Vi Nguyen, Penfold, Sally A., Thallas-Bonke, Vicki, Tan, Sih Mm, Ramm, Georg, Van Bergen, Nicole J., Henstridge, Darren C., Sourris, Karly C., Harcourt, Brooke E., Trounce, Ian A., Robb, Portia M., Laskowski, Adrienne, McGee, Sean L., Genders, Amanda J., Walder, Ken, Drew, Brian G., Gregorevic, Paul, Qian, Hongwei, Thomas, Merlin C., Jerums, George, Macisaac, Richard J., Skene, Alison, Ekinci, Elif I., Wijeyeratne, Xiaonan W., Gallo, Linda A., Heiman-Edelstein, Michal, Ryan, Michael T. ... Forbes, Josephine M. (2016). Deficiency in apoptosis-inducing factor recapitulates chronic kidney disease via aberrant mitochondrial homeostasis. Diabetes, 65 (4), 1085-1098. doi: 10.2337/db15-0864

Deficiency in apoptosis-inducing factor recapitulates chronic kidney disease via aberrant mitochondrial homeostasis

2016

Conference Publication

The SGLT2 Inhibitor, Empagliflozin, Attenuates Some Markers of Renal Fibrosis without Improving Albuminuria in Diabetic Db/Db Mice

Gallo, Linda A., Ward, Micheal S., Fotheringham, Amelia K., Zhuang, Aowen, Koepsell, Hermann, Vallon, Volker, Pollock, Carol, Panchapakesan, Usha and Forbes, Josephine M. (2016). The SGLT2 Inhibitor, Empagliflozin, Attenuates Some Markers of Renal Fibrosis without Improving Albuminuria in Diabetic Db/Db Mice. Experimental Biology 2016 Meeting, San Diego, CA United States, 1-5 April 2016. Hoboken, NJ United States: John Wiley & Sons. doi: 10.1096/fasebj.30.1_supplement.740.18

The SGLT2 Inhibitor, Empagliflozin, Attenuates Some Markers of Renal Fibrosis without Improving Albuminuria in Diabetic Db/Db Mice

2016

Journal Article

Mapping time-course mitochondrial adaptations in the kidney in experimental diabetes

Coughlan, Melinda T., Nguyen, Tuong-Vi, Penfold, Sally A., Higgins, Gavin C., Thallas-Bonke, Vicki, Tan, Sih Min, Van Bergen, Nicole J., Sourris, Karly C., Harcourt, Brooke E., Thorburn, David R., Trounce, Ian A., Cooper, Mark E. and Forbes, Josephine M. (2016). Mapping time-course mitochondrial adaptations in the kidney in experimental diabetes. Clinical Science, 130 (9), 711-720. doi: 10.1042/CS20150838

Mapping time-course mitochondrial adaptations in the kidney in experimental diabetes

2016

Journal Article

Synbiotics easing renal failure by improving gut microbiology (SYNERGY): a randomized trial

Rossi, Megan, Johnson, David W., Morrison, Mark, Pascoe, Elaine M., Coombes, Jeff S., Forbes, Josephine M., Szeto, Cheuk-Chun, McWhinney, Brett C., Ungerer, Jacobus P. J. and Campbell, Katrina L. (2016). Synbiotics easing renal failure by improving gut microbiology (SYNERGY): a randomized trial. Clinical Journal of the American Society of Nephrology, 11 (2), 223-231. doi: 10.2215/CJN.05240515

Synbiotics easing renal failure by improving gut microbiology (SYNERGY): a randomized trial

2016

Journal Article

Tapping into mitochondria to find novel targets for diabetes complications

Fleming, Nicole B., Gallo, Linda, Ward, Micheal S. and Forbes, Josephine M. (2016). Tapping into mitochondria to find novel targets for diabetes complications. Current Drug Targets, 17 (12), 1341-1349. doi: 10.2174/1389450116666150727114410

Tapping into mitochondria to find novel targets for diabetes complications

2015

Journal Article

Abdominal obesity and brain atrophy in type 2 diabetes mellitus

Climie, Rachel E. D., Moran, Chris, Callisaya, Michele, Blizzard, Leigh, Sharman, James E., Venn, Alison, Phan, Thanh G., Beare, Richard, Forbes, Josephine, Blackburn, Nicholas B. and Srikanth, Velandai (2015). Abdominal obesity and brain atrophy in type 2 diabetes mellitus. PloS One, 10 (11) e0142589, e0142589. doi: 10.1371/journal.pone.0142589

Abdominal obesity and brain atrophy in type 2 diabetes mellitus

2015

Conference Publication

IL-22-mediated suppression of islet inflammation

McGuckin, Mike, Hasnain, Sumaira Z., Borg, Danielle J., Loudovaris, Thomas, Kay, Thomas W., Thomas, Helen E., Whitehead, Jonathon P., Forbes, Josephine M. and Prins, John B. (2015). IL-22-mediated suppression of islet inflammation. IPITA/IXA/CTS Joint Congress, Melbourne Australia, Nov 15-19, 2015. HOBOKEN: LIPPINCOTT WILLIAMS & WILKINS.

IL-22-mediated suppression of islet inflammation